INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← Metabolism / Health Desk

Low-GI patterns: a modest HbA1c effect across varied trials

A randomized-trial synthesis found a small average improvement, alongside substantial differences between trial results.

Whole-food ingredients prepared without added oil

Illustrative food image, not a photograph of the study intervention.

A dietary pattern comparison

This review examined low glycaemic index or glycaemic load dietary patterns in people with diabetes. Eligible randomized trials lasted at least three weeks, and the searches extended through 13 May 2021. The investigators identified 29 trial comparisons involving 1,617 participants with type 1 or type 2 diabetes. Most participants were middle aged, overweight or obese, and had moderately controlled type 2 diabetes treated with glucose-lowering drugs or insulin. The comparison was lower-GI or lower-GL patterns against higher-GI or higher-GL control diets. That is a pattern-level question, not a test establishing that one particular food independently explains the pooled result.

Chiavaroli L, Lee D, Ahmed A, Cheung A et al.. BMJ (Clinical research ed.), 2021. PMID 34348965 · DOI

The primary number and its spread

HbA1c was the primary outcome. Compared with the higher-GI or higher-GL control diets, the lower-GI or lower-GL patterns reduced HbA1c by an average of 0.31 percentage points. The 95% confidence interval extended from a reduction of 0.42 to 0.19 percentage points, and the reported P value was below 0.001. The review also reported substantial heterogeneity, with I-squared of 75%. Both facts matter: the average favoured the lower-GI or lower-GL patterns, but the trial results were not uniform. The pooled figure should therefore stay attached to its comparison diets and variability, rather than becoming a promised individual response.

Chiavaroli L, Lee D, Ahmed A, Cheung A et al.. BMJ (Clinical research ed.), 2021. PMID 34348965 · DOI

Other markers did not all move together

The review reported reductions in fasting glucose, LDL cholesterol, non-HDL cholesterol, apo B, triglycerides, body weight, BMI and C reactive protein. It also reported a dose-response result for systolic blood pressure. Not every measured marker changed: there were no reductions in blood insulin, HDL cholesterol, waist circumference or diastolic blood pressure. The investigators rated the certainty of evidence high for the HbA1c reduction and moderate for most secondary outcomes, with imprecision the main reason for downgrading. This is a useful distinction between the primary result and the broader set of markers, rather than a claim that every cardiometabolic measurement improved together.

Chiavaroli L, Lee D, Ahmed A, Cheung A et al.. BMJ (Clinical research ed.), 2021. PMID 34348965 · DOI

Keep treatment and disclosures in view

The authors describe small improvements beyond concurrent glucose-lowering drug or insulin treatment, not a demonstration that dietary patterns replace those treatments. The 29 comparisons concern measured glycaemic and cardiometabolic targets; they do not establish a reduction in clinical complications in this abstract. The disclosure statement reports support for the submitted work from Diabetes Canada and a publicly supported research centre, alongside multiple author relationships with food-industry organizations. Those relationships deserve visibility without being treated as proof that the result is false. Substantial heterogeneity also remains part of the interpretation, even though the review rated the HbA1c evidence as high certainty.

Chiavaroli L, Lee D, Ahmed A, Cheung A et al.. BMJ (Clinical research ed.), 2021. PMID 34348965 · DOI